Pfizer and German partner BioNTech released data from a clinical trial last week indicating their vaccine was safe and effective for children ages 5 to 11 at one-third of the dose given to adolescents and adults. | | News Alert Thursday, October 7 | | | | | | | |
No comments:
Post a Comment